Fri, Jul 25, 2014, 9:03 AM EDT - U.S. Markets open in 27 mins.


% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • fudfighter4 fudfighter4 Jul 1, 2013 4:33 PM Flag

    Tom.berry169 - that $6 billion market cap ...

    Today it became all but a certainty.

    At the current average biotech valuation, 40,000 patients using Arikace would get us there.

    65,000 with CF in the US/Europe for whom Arikace will now be the first-choice antibiotic.

    100,000 with NTM in the US/Europe for whom Arikace will be the only-choice antibiotic - assuming the NTM study (vs placebo) also delivers a significant reduction in bacterial density.

    Today that became far more likely - as did the approval of Arikace for pneumonia / drug-resistant Tuberculosis.

    Thanks for asking :-)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
17.61Jul 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.